MK

Mohammad Kamruzzaman

Active Director Director DIN 09591930
DIN 09591930 First appointment Apr 2022 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Mohammad Kamruzzaman

Data last updated:

Mohammad Kamruzzaman is a Director at Texsus Multispeciality & Diagonistic Center Private Limited (since 2022). The company operates in Healthcare.

DIN 09591930
Primary Designation Director
Industry Healthcare
First Appointment 22 Apr 2022
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director22 Apr 20222021Active

Board colleagues of Mohammad Kamruzzaman

Directorship timeline

Open interactive timeline →
Texsus Multispeciality & Diagonistic Center Private Limited
Premium access

Shareholding and investment profile for Mohammad Kamruzzaman

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mohammad Kamruzzaman

Mohammad Kamruzzaman currently holds 1 directorship: Texsus Multispeciality & Diagonistic Center Private Limited (Director, since 22 Apr 2022).

Mohammad Kamruzzaman was first appointed on 22 Apr 2022 as Director at Texsus Multispeciality & Diagonistic Center Private Limited.

The current boards of Mohammad Kamruzzaman's companies include Chand Sultana (Texsus Multispeciality & Diagonistic Center Private Limited), Rahul Karmakar (Texsus Multispeciality & Diagonistic Center Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available